Skip to content
    Samsara BioCapital logo

    Samsara BioCapital

    Palo Alto, California, United StatesFounded 2016
    www.samsaracap.comLinkedIn
    Biotech & Life SciencesHealthcare

    Samsara BioCapital is a venture capital firm founded in 2016 and based in Palo Alto, California. The firm partners with scientists and entrepreneurs to translate cutting-edge science into transformative medicines for patients, investing in innovative therapeutics across the biotech and life sciences sectors.

    57% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (43% of deals). Average disclosed round size is $99.0M (across 90 rounds with reported amounts).

    Find people at Samsara BioCapital on Goldilocks AI

    Portfolio

    84

    Fund Size

    $310.1M

    Top Stage

    Series B

    Last 12 Mo

    11

    Team

    SA

    Srini Akkaraju, MD, PhD

    Founder & Managing Partner

    AB

    Abe Bassan

    Partner

    AE

    Alan Eisenberg

    Venture Partner

    BS

    Betsy Santos

    Venture Partner, Chief People Officer

    DS

    Dan Spiegelman

    Venture Partner

    DP

    David Parry, PhD

    Venture Partner

    ED

    Eric Dobmeier, JD

    Venture Partner

    GR

    Guna Rajagopal, PhD

    Venture Partner

    JP

    Jim P. Edwards, PhD

    Venture Partner

    JO

    John Orwin

    Venture Partner

    KG

    Keith Gottesdiener, MD

    Venture Partner

    MM

    Marcos Milla, PhD

    Venture Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    96 investments
    CompanyRoundAmountDate
    Ambrosia Biosciences Inc. logoAmbrosia Biosciences Inc.Series B$100MMar 2026
    PPrimmune Therapeutics IncSeries B$8.6MJan 2026
    EpiBiologics logoEpiBiologicsSeries B$107MJan 2026
    SSidewinder TherapeuticsSeries B$137MJan 2026
    Sidewinder logoSidewinderSeries B$137MJan 2026
    Memento Medicines logoMemento MedicinesSeries A$93MJan 2026
    CClaris BioSeries B—Jan 2026
    Artiva Biotherapeutics logoArtiva BiotherapeuticsSeries B$120MJan 2026
    PsiThera logoPsiTheraSeries A$47.5MDec 2025
    Link Cell Therapies logoLink Cell TherapiesSeries A$60MDec 2025
    Excellergy Therapeutics logoExcellergy TherapeuticsSeries A$70MOct 2025
    SpyGlass Pharma logoSpyGlass PharmaSeries D$75MJun 2025
    Alpheus Medical logoAlpheus MedicalSeries B$52MMay 2025
    Surrozen logoSurrozenSeries D$175MMar 2025
    AAbcuro, Inc.Series C$200MFeb 2025
    Elektrofi, Inc. logoElektrofi, Inc.Series C$112.3MOct 2024
    EElektrofiSeries C$112.3MOct 2024
    Alpha-9 Oncology logoAlpha-9 OncologySeries C$175MOct 2024
    Inventiva logoInventivaUnknown$410MOct 2024
    Pathalys logoPathalysSeries B$105MAug 2024
    LLeap TherapeuticsSeries B$40MApr 2024
    Alumis logoAlumisSeries C$259MMar 2024
    OrsoBio logoOrsoBioSeries B$67MJan 2024
    Neoleukin Therapeutics logoNeoleukin TherapeuticsSeries A$68.5MJan 2024
    OrsoBio logoOrsoBioSeries A$60MNov 2023
    Page 1 of 4

    Top Co-Investors

    RA Capital Management24 shared
    Cormorant Asset Management14 shared
    SR One12 shared
    Rock Springs Capital11 shared
    Catalys Pacific10 shared
    OrbiMed10 shared
    Illumina Ventures9 shared
    Lightspeed Venture Partners9 shared
    Casdin Capital9 shared
    Surveyor Capital9 shared
    Logos Capital9 shared
    Foresite Capital9 shared
    HBM Healthcare Investments9 shared
    Frazier Life Sciences8 shared
    Cowen Healthcare Investments8 shared
    BVF Partners L.P.7 shared
    Vivo Capital7 shared
    Pfizer Ventures7 shared
    Eli Lilly and Company7 shared
    Menlo Ventures7 shared

    Last updated: 7 September 2026